KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBT Margin (2016 - 2025)

Historic EBT Margin for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to 97.86%.

  • Pacific Biosciences Of California's EBT Margin rose 540800.0% to 97.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 325.52%, marking a year-over-year decrease of 974100.0%. This contributed to the annual value of 200.98% for FY2024, which is 423100.0% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported EBT Margin of 97.86% as of Q3 2025, which was up 540800.0% from 105.35% recorded in Q2 2025.
  • Pacific Biosciences Of California's EBT Margin's 5-year high stood at 6.85% during Q4 2024, with a 5-year trough of 1147.62% in Q1 2025.
  • Over the past 5 years, Pacific Biosciences Of California's median EBT Margin value was 189.22% (recorded in 2021), while the average stood at 236.68%.
  • Examining YoY changes over the last 5 years, Pacific Biosciences Of California's EBT Margin showed a top increase of 3759100bps in 2025 and a maximum decrease of -9461900bps in 2025.
  • Over the past 5 years, Pacific Biosciences Of California's EBT Margin (Quarter) stood at 189.22% in 2021, then crashed by -63bps to 308.5% in 2022, then surged by 54bps to 141.78% in 2023, then soared by 105bps to 6.85% in 2024, then tumbled by -1528bps to 97.86% in 2025.
  • Its last three reported values are 97.86% in Q3 2025, 105.35% for Q2 2025, and 1147.62% during Q1 2025.